| Identification | Back Directory | [Name]
Aplaviroc | [CAS]
461443-59-4 | [Synonyms]
AK 602 ONO 4128 Aplaviroc GW 873140 GSK 873140 GWNOTCOIYUNTQP-FQLXRVMXSA-N AK 602; AK-602; GW 873140; GW873140; ONO 4128 4-[4-[[(3R)-1-Butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]benzoic acid Benzoic acid, 4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl]phenoxy]- | [Molecular Formula]
C33H43N3O6 | [MDL Number]
MFCD22200785 | [MOL File]
461443-59-4.mol | [Molecular Weight]
577.71 |
| Chemical Properties | Back Directory | [Boiling point ]
800.6±65.0 °C(Predicted) | [density ]
1.29 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
4.29±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
Treatment of HIV infection. | [in vivo]
The concentration of Aplaviroc (AK602) reached the maximal concentration immediately after intraperitoneal administration and decreased rapidly[2].
Aplaviroc (AK602, 60 mg/kg, bid, daily) suppresses R5 HIV-1 viremia in hu-PBMC-NOG mice[2].
| Animal Model: | hu-PBMC-NOG mice[2]. | | Dosage: | 60 mg/kg. | | Administration: | Single intraperitoneal administration, bid, daily. | | Result: | The numbers of CD4+ cells/μL in saline-treated mice were significantly less than those of AK602-treated, ddI-treated, or uninfected mice. |
| [IC 50]
HIV-1Ba-L: 0.4 nM (IC50); HIV-1JRFL: 0.1 nM (IC50); HIV-1MOKW: 0.2 nM (IC50); CCR5 |
|
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
cjbscvictory
|
| Telephone: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Telephone: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|